Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1723-1724

  Uchiyama, Michihiro ^a   Ikeda, Takashi ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMATINIB; LACTATE DEHYDROGENASE; RISTOCETIN;

AGED; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME 22Q; CHROMOSOME 9Q; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HEMATOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE 46,XY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; MALE; MEGAKARYOCYTE; MYELOBLAST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VON WILLEBRAND DISEASE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; VON WILLEBRAND DISEASES;

EID: 70249105346     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.05.011     Document Type: Article

References (4)

1. Michiels J.J., Budde U., van der Planken M., van Vliet H.H., Schroyens W., and Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 14 (2001) 401-436
2. Mohri H. Acquired von Willebrand syndrome: features and management. Am J Hematol 81 (2006) 616-623
3. Federici A.B. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol 43 (2006) S48-58
4. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 35 (2006) 2408-2417